Literature DB >> 34854975

The need for early Kasai portoenterostomy: a Western Pediatric Surgery Research Consortium study.

Lorraine I Kelley-Quon1,2, Eveline Shue3, Rita V Burke4, Caitlin Smith5, Karen Kling6, Elaa Mahdi3, Shadassa Ourshalimian3, Michael Fenlon3, Matthew Dellinger5, Stephen B Shew7, Justin Lee8, Benjamin Padilla8, Thomas Inge9, Jonathan Roach9, Ahmed I Marwan9, Katie W Russell10, Romeo Ignacio6, Elizabeth Fialkowski11, Amar Nijagal12, Cecilia Im12, Kenneth S Azarow11, Daniel J Ostlie8, Kasper Wang3.   

Abstract

PURPOSE: The purpose of this study was to investigate factors impacting transplant-free survival among infants with biliary atresia.
METHODS: A multi-institutional, retrospective cohort study was performed at nine tertiary-level children's hospitals in the United States. Infants who underwent Kasai portoenterostomy (KP) from January 2009 to May 2017 were identified. Clinical characteristics included age at time of KP, steroid use, surgical approach, liver pathology, and surgeon experience. Likelihood of transplant-free survival (TFS) was evaluated using logistic regression, adjusting for patient and surgeon-level factors. Secondary outcomes at 1 year included readmission, cholangitis, reoperation, mortality, and biliary clearance.
RESULTS: Overall, 223 infants underwent KP, and 91 (40.8%) survived with their native liver. Mean age at surgery was 63.9 days (± 24.7 days). At 1 year, 78.5% experienced readmission, 56.9% developed cholangitis, 3.8% had a surgical revision, and 5 died. Biliary clearance at 3 months was achieved in 76.6%. Controlling for patient and surgeon-level factors, each additional day of age toward operation was associated with a 2% decrease in likelihood of TFS (OR 0.98, 95% CI 0.97-0.99).
CONCLUSION: Earlier surgical intervention by Kasai portoenterostomy at tertiary-level centers significantly increases likelihood for TFS. Policy-level interventions to facilitate early screening and surgical referral for infants with biliary atresia are warranted to improve outcomes.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Biliary atresia; Kasai portoenterostomy; Liver transplant; Transplant-free survival

Mesh:

Year:  2021        PMID: 34854975      PMCID: PMC8742784          DOI: 10.1007/s00383-021-05047-1

Source DB:  PubMed          Journal:  Pediatr Surg Int        ISSN: 0179-0358            Impact factor:   1.827


  22 in total

1.  High-volume surgeons vs high-volume hospitals: are best outcomes more due to who or where?

Authors:  Paul G Toomey; Anthony F Teta; Krishen D Patel; Sharona B Ross; Alexander S Rosemurgy
Journal:  Am J Surg       Date:  2015-11-02       Impact factor: 2.565

2.  Surgeon volume impact on outcomes and cost of adrenal surgeries.

Authors:  Z Al-Qurayshi; R Robins; J Buell; E Kandil
Journal:  Eur J Surg Oncol       Date:  2016-06-23       Impact factor: 4.424

Review 3.  Long-term prognosis and factors affecting biliary atresia from experience over a 25 year period.

Authors:  Hong-Shiee Lai; Wei-Jao Chen; Chiu-Ching Chen; Wen-Tsung Hung; Mei-Hwei Chang
Journal:  Chang Gung Med J       Date:  2006 May-Jun

4.  Incidence of Biliary Atresia and Timing of Hepatoportoenterostomy in the United States.

Authors:  Perri C Hopkins; Nada Yazigi; Cade M Nylund
Journal:  J Pediatr       Date:  2017-06-01       Impact factor: 4.406

5.  Management of Biliary Atresia in France 1986 to 2015: Long-term Results.

Authors:  Martina Fanna; Guillaume Masson; Carmen Capito; Muriel Girard; Florent Guerin; Bogdan Hermeziu; Alain Lachaux; Bertrand Roquelaure; Frédéric Gottrand; Pierre Broue; Alain Dabadie; Thierry Lamireau; Emmanuel Jacquemin; Christophe Chardot
Journal:  J Pediatr Gastroenterol Nutr       Date:  2019-10       Impact factor: 2.839

6.  Impact of surgeon and hospital volume on mortality, length of stay, and cost of pancreaticoduodenectomy.

Authors:  Laura M Enomoto; Niraj J Gusani; Peter W Dillon; Christopher S Hollenbeak
Journal:  J Gastrointest Surg       Date:  2013-12-03       Impact factor: 3.452

Review 7.  Biliary atresia: Indications and timing of liver transplantation and optimization of pretransplant care.

Authors:  Shikha S Sundaram; Cara L Mack; Amy G Feldman; Ronald J Sokol
Journal:  Liver Transpl       Date:  2017-01       Impact factor: 5.799

8.  Impact of age at Kasai operation on its results in late childhood and adolescence: a rational basis for biliary atresia screening.

Authors:  Marie-Odile Serinet; Barbara E Wildhaber; Pierre Broué; Alain Lachaux; Jacques Sarles; Emmanuel Jacquemin; Frédéric Gauthier; Christophe Chardot
Journal:  Pediatrics       Date:  2009-05       Impact factor: 7.124

9.  Improving outcomes of biliary atresia: French national series 1986-2009.

Authors:  Christophe Chardot; Chantal Buet; Marie-Odile Serinet; Jean-Louis Golmard; Alain Lachaux; Bertrand Roquelaure; Frédéric Gottrand; Pierre Broué; Alain Dabadie; Frédéric Gauthier; Emmanuel Jacquemin
Journal:  J Hepatol       Date:  2013-02-08       Impact factor: 25.083

10.  Number of cholangitis episodes as a prognostic marker to predict timing of liver transplantation in biliary atresia patients after Kasai portoenterostomy.

Authors:  Szu-Ying Chen; Chieh-Chung Lin; Yu-Tse Tsan; Wei-Cheng Chan; Jiaan-Der Wang; Yi-Jung Chou; Ching-Heng Lin
Journal:  BMC Pediatr       Date:  2018-04-02       Impact factor: 2.125

View more
  3 in total

1.  Selective enlargement of left lateral segment liver volume as a potential diagnostic predictor for biliary atresia.

Authors:  Kenji Santo; Yuichi Takama; Yuki Hirose; Jun Matsui; Ririko Takemura; Kei Nakada; Takashi Sasaki
Journal:  Pediatr Surg Int       Date:  2022-09-15       Impact factor: 2.003

Review 2.  Biliary atresia and congenital disorders of the extrahepatic bile ducts.

Authors:  Ali Islek; Gokhan Tumgor
Journal:  World J Gastrointest Pharmacol Ther       Date:  2022-07-05

3.  Biliary Atresia in 2021: Epidemiology, Screening and Public Policy.

Authors:  Richard A Schreiber; Sanjiv Harpavat; Jan B F Hulscher; Barbara E Wildhaber
Journal:  J Clin Med       Date:  2022-02-14       Impact factor: 4.241

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.